There has been an exhaustive amount of activity around
Catalent (CTLT). The company is in the spotlight due to significant changes including the
sell agreement with
Ardena and plans to sell its oral solids facility in New Jersey. It's also reportedly outperforming the healthcare sector. However, regulatory hurdles seem to emerge with the FTC receiving requests to block the sale of Catalent to
Novo Holdings, receiving support from consumer and labor groups. This situation is further exacerbated by US Senator Warren calling for an investigation into the deal. Amid all this, significant stake shifts are happening with multiple firms including Kapitalo Investimentos Ltda, Squarepoint Ops LLC, and Contravisory Investment Management. Catalent also encounters potential downgrade issues and an FDA investigation into lapses at a facility being sold. Earnings and revenue reportedly exceed estimates, leading to stock price surges. The deal with Novo Holdings is causing additional buzz, either attracting investors or causing them to question their position. Novo Nordisk, the parent company of Novo Holdings, however, is pushing forward with purchasing Catalent to boost supply lines.
Catalent CTLT News Analytics from Sat, 15 Nov 2014 08:00:00 GMT to Thu, 17 Oct 2024 21:27:09 GMT -
Rating 1
- Innovation 3
- Information 5
- Rumor -2
